Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.
Zacks Investment Research on MSN5h
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyShares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...
Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...
Nidhi Shashikumar is a data scientist and business intelligence expert with over 7 years of experience in healthcare ...
GENEVA: The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid ...
Zacks Investment Research on MSN23h
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to NoteIn the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback